The BIRD Foundation — an established binational research and development ("R&D") fund — supports industrial collaborations between Israeli and U.S. companies. Since its establishment in 1977, BIRD has ...
Kadimastem Ltd. and Itolerance Inc. have held a type B pre-IND meeting with the FDA regarding the development of ITOL-102, an investigational biologic for the treatment and potential cure of type 1 ...
Approval Follows Successful Pre-IND Meeting with the U.S. FDA on iTOL-102, a Potential Cure for Type 1 diabetes that would circumvent the need for life-long immunosuppression drugs ZURICH, July 17, ...
NLS Pharmaceutics Ltd. (Nasdaq: NLSP”) (“NLS”) and Kadimastem Ltd. (“Kadimastem”), a clinical-stage company specializing in "off-the-shelf" allogeneic cell therapy products for neurodegenerative ...
Itolerance Inc. and Kadimastem Ltd. have submitted a meeting request to the FDA's INTERACT committee for ITOL-102, which is under development as a potential cure for type 1 diabetes without the need ...
DRI to assist in advancing potential of iTOL-100 to enable engraftment and long-term survival of transplanted insulin producing stem cells without the use of chronic immunosuppression Pre-clinical ...
iTOL-100 technology has broad applicability and can be applied to both allogenic and stem cell-derived organoids across a number of diseases. Manufacturing agreement supports advancement of iTolerance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results